vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $75.1M, roughly 1.6× MEDIFAST INC). On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs -36.9%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $-6.6M). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs -34.4%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

HIPO vs MED — Head-to-Head

Bigger by revenue
HIPO
HIPO
1.6× larger
HIPO
$120.4M
$75.1M
MED
Growing faster (revenue YoY)
HIPO
HIPO
+55.1% gap
HIPO
18.2%
-36.9%
MED
More free cash flow
HIPO
HIPO
$15.7M more FCF
HIPO
$9.1M
$-6.6M
MED
Faster 2-yr revenue CAGR
HIPO
HIPO
Annualised
HIPO
18.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIPO
HIPO
MED
MED
Revenue
$120.4M
$75.1M
Net Profit
$6.0M
Gross Margin
69.4%
Operating Margin
5.6%
-10.4%
Net Margin
5.0%
Revenue YoY
18.2%
-36.9%
Net Profit YoY
-86.4%
EPS (diluted)
$0.31
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
MED
MED
Q4 25
$120.4M
$75.1M
Q3 25
$120.6M
$89.4M
Q2 25
$117.3M
$105.6M
Q1 25
$110.3M
$115.7M
Q4 24
$101.9M
$119.0M
Q3 24
$95.5M
$140.2M
Q2 24
$89.6M
$168.6M
Q1 24
$85.1M
$174.7M
Net Profit
HIPO
HIPO
MED
MED
Q4 25
$6.0M
Q3 25
$98.1M
$-2.3M
Q2 25
$1.3M
$2.5M
Q1 25
$-47.7M
$-772.0K
Q4 24
$44.2M
Q3 24
$-8.5M
$1.1M
Q2 24
$-40.5M
$-8.2M
Q1 24
$-35.7M
$8.3M
Gross Margin
HIPO
HIPO
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
HIPO
HIPO
MED
MED
Q4 25
5.6%
-10.4%
Q3 25
81.3%
-4.6%
Q2 25
3.4%
-1.0%
Q1 25
-41.3%
-1.1%
Q4 24
46.3%
0.6%
Q3 24
-5.4%
1.5%
Q2 24
-40.7%
-4.7%
Q1 24
-38.7%
4.5%
Net Margin
HIPO
HIPO
MED
MED
Q4 25
5.0%
Q3 25
81.3%
-2.5%
Q2 25
1.1%
2.3%
Q1 25
-43.2%
-0.7%
Q4 24
43.4%
Q3 24
-8.9%
0.8%
Q2 24
-45.2%
-4.8%
Q1 24
-42.0%
4.8%
EPS (diluted)
HIPO
HIPO
MED
MED
Q4 25
$0.31
$-1.64
Q3 25
$3.77
$-0.21
Q2 25
$0.05
$0.22
Q1 25
$-1.91
$-0.07
Q4 24
$1.81
$0.08
Q3 24
$-0.34
$0.10
Q2 24
$-1.64
$-0.75
Q1 24
$-1.47
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
MED
MED
Cash + ST InvestmentsLiquidity on hand
$218.3M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$436.1M
$198.9M
Total Assets
$1.9B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
MED
MED
Q4 25
$218.3M
$167.3M
Q3 25
$247.7M
$173.5M
Q2 25
$198.9M
$162.7M
Q1 25
$140.9M
$164.6M
Q4 24
$197.6M
$162.3M
Q3 24
$191.2M
$170.0M
Q2 24
$175.9M
$163.5M
Q1 24
$223.4M
$156.4M
Stockholders' Equity
HIPO
HIPO
MED
MED
Q4 25
$436.1M
$198.9M
Q3 25
$421.5M
$214.7M
Q2 25
$332.5M
$216.0M
Q1 25
$322.8M
$211.0M
Q4 24
$362.1M
$210.1M
Q3 24
$326.4M
$207.3M
Q2 24
$322.6M
$205.3M
Q1 24
$351.2M
$211.0M
Total Assets
HIPO
HIPO
MED
MED
Q4 25
$1.9B
$248.0M
Q3 25
$1.9B
$268.2M
Q2 25
$1.7B
$269.3M
Q1 25
$1.5B
$280.0M
Q4 24
$1.5B
$284.2M
Q3 24
$1.5B
$291.2M
Q2 24
$1.5B
$293.5M
Q1 24
$1.5B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
MED
MED
Operating Cash FlowLast quarter
$9.2M
$-5.3M
Free Cash FlowOCF − Capex
$9.1M
$-6.6M
FCF MarginFCF / Revenue
7.6%
-8.8%
Capex IntensityCapex / Revenue
0.1%
1.8%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$14.8M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
MED
MED
Q4 25
$9.2M
$-5.3M
Q3 25
$16.9M
$12.1M
Q2 25
$24.7M
$-3.4M
Q1 25
$-35.6M
$3.4M
Q4 24
$47.5M
$-4.9M
Q3 24
$46.8M
$9.1M
Q2 24
$-10.6M
$13.1M
Q1 24
$17.7M
$7.3M
Free Cash Flow
HIPO
HIPO
MED
MED
Q4 25
$9.1M
$-6.6M
Q3 25
$16.8M
$10.8M
Q2 25
$24.6M
$-4.8M
Q1 25
$-35.7M
$1.9M
Q4 24
$47.2M
$-7.2M
Q3 24
$7.7M
Q2 24
$-10.7M
$11.1M
Q1 24
$17.6M
$5.4M
FCF Margin
HIPO
HIPO
MED
MED
Q4 25
7.6%
-8.8%
Q3 25
13.9%
12.0%
Q2 25
21.0%
-4.5%
Q1 25
-32.4%
1.6%
Q4 24
46.3%
-6.1%
Q3 24
5.5%
Q2 24
-11.9%
6.6%
Q1 24
20.7%
3.1%
Capex Intensity
HIPO
HIPO
MED
MED
Q4 25
0.1%
1.8%
Q3 25
0.1%
1.5%
Q2 25
0.1%
1.3%
Q1 25
0.1%
1.3%
Q4 24
0.3%
1.9%
Q3 24
0.0%
1.0%
Q2 24
0.1%
1.1%
Q1 24
0.1%
1.1%
Cash Conversion
HIPO
HIPO
MED
MED
Q4 25
1.53×
Q3 25
0.17×
Q2 25
19.00×
-1.36×
Q1 25
Q4 24
1.07×
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons